Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise healthy male subjects.

Official Title
-----------------
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.

Conditions
-----------------
Metabolism and Nutrition Disorder, Obesity

Intervention / Treatment
-----------------
* Drug: NNC9204-0530
* Drug: liraglutide
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male, age between (both inclusive) 18 and 55 years at the time of signing inform consent Overweight or obese but otherwise healthy male subjects; BMI of between or equal to 27.0 and 35.0 kg/m^2 Exclusion Criteria: Thyroid stimulating hormone values outside 0.4-6.0 mIU/l HbA1c (glycated hemoglobin) above or equal to 6.5% Any clinically relevant ECG (electrocardiogram) findings (e.g. 2nd or 3rd degree AV-block), in particular subjects with repeated demonstration of a QTcF (QT interval corrected by Fridericia formula) interval above 430 ms A history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) The use of concomitant medications that prolong the QT/QTc interval Obesity caused by endocrinology disorders (e.g. Cushing's Syndrome) Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 Calcitonin above 50 ng/L History of pancreatitis (acute or chronic)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Part 1<br> | Drug: NNC9204-0530<br>* Administered as single subcutaneous (s.c., under the skin) injections.<br>Drug: placebo<br>* Administered as single subcutaneous (s.c., under the skin) injections.<br>|
| Experimental: Part 2<br> | Drug: NNC9204-0530<br>* Administered as single subcutaneous (s.c., under the skin) injections.<br>Drug: liraglutide<br>* Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.<br>Drug: placebo<br>* Administered as single subcutaneous (s.c., under the skin) injections.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of treatment emergent adverse events recorded |  | From time of dosing of NNC9204-0530 (Day 1) until completion of the follow-up visit (Day 21-27) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the NNC9204-0530 serum concentration-time curve |  | From dosing visit to infinity calculated on 0-24 days NNC9204-0530 serum concentration-curve based on 21 sampling points | 
| Maximum concentration of NNC9204-0530 in serum |  | From dosing visit to infinity calculated on 0-24 days NNC9204-0530 serum concentration-curve based on 21 sampling points | 
| The time to maximum concentration of NNC9204-0530 in serum |  | From dosing visit to infinity calculated on 0-24 days NNC9204-0530 serum concentration-curve based on 21 sampling points | 
| The terminal half-life of NNC9204-0530 |  | From dosing visit to infinity calculated on 0-24 days NNC9204-0530 serum concentration-curve based on 21 sampling points |